ENDOCYTE, INC. v. POINT BIOPHARMA GLOBAL INC.

COMPLAINT against All Defendants, filed by All Plaintiffs. (Filing fee $405, receipt number AINSDC-8206974) (Attachments: # 1 Civil Cover Sheet, # 2 Proposed Summons, # 3 Exhibit A -10,624,970 Patent Certified, # 4 Exhibit B Nov 11, 2022 POINT-Lantheus Agreement)(Hidde, Kandi) (Entered: 06/13/2024)

2024-06-13

1

Download

COMPLAINT against All Defendants, filed by All Plaintiffs. (Filing fee $405, receipt number AINSDC-8206974) (Attachments: # 1 Civil Cover Sheet, # 2 Proposed Summons, # 3 Exhibit A -10,624,970 Patent Certified, # 4 Exhibit B Nov 11, 2022 POINT-Lantheus Agreement)(Hidde, Kandi) (Entered: 06/13/2024)

2024-06-13

2

View

COMPLAINT against All Defendants, filed by All Plaintiffs. (Filing fee $405, receipt number AINSDC-8206974) (Attachments: # 1 Civil Cover Sheet, # 2 Proposed Summons, # 3 Exhibit A -10,624,970 Patent Certified, # 4 Exhibit B Nov 11, 2022 POINT-Lantheus Agreement)(Hidde, Kandi) (Entered: 06/13/2024)

2024-06-13

2

View

COMPLAINT against All Defendants, filed by All Plaintiffs. (Filing fee $405, receipt number AINSDC-8206974) (Attachments: # 1 Civil Cover Sheet, # 2 Proposed Summons, # 3 Exhibit A -10,624,970 Patent Certified, # 4 Exhibit B Nov 11, 2022 POINT-Lantheus Agreement)(Hidde, Kandi) (Entered: 06/13/2024)

2024-06-13

2

View

COMPLAINT against All Defendants, filed by All Plaintiffs. (Filing fee $405, receipt number AINSDC-8206974) (Attachments: # 1 Civil Cover Sheet, # 2 Proposed Summons, # 3 Exhibit A -10,624,970 Patent Certified, # 4 Exhibit B Nov 11, 2022 POINT-Lantheus Agreement)(Hidde, Kandi) (Entered: 06/13/2024)

2024-06-13

2

View

NOTICE of Appearance by Kandi Kilkelly Hidde on behalf of Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Hidde, Kandi) (Entered: 06/13/2024)

2024-06-13

1

View

NOTICE of Appearance by Patricia Roman Hass on behalf of Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Roman Hass, Patricia) (Entered: 06/13/2024)

2024-06-13

1

View

Rule 7.1 Disclosure Statement by ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Hidde, Kandi) (Entered: 06/13/2024)

2024-06-13

1

View

MOTION for Attorney(s) Melissa B. Collins to Appear pro hac vice (Filing fee $100, receipt number AINSDC-8207169), filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # 1 Exhibit A - Certification, # 2 Text of Proposed Order)(Hidde, Kandi) (Entered: 06/13/2024)

2024-06-13

1

View

MOTION for Attorney(s) M. Elaine Horn to Appear pro hac vice (Filing fee $100, receipt number AINSDC-8207175), filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # 1 Exhibit A - Certification, # 2 Text of Proposed Order)(Hidde, Kandi) (Entered: 06/13/2024)

2024-06-13

1

View

MOTION for Attorney(s) Jessamyn S. Berniker to Appear pro hac vice (Filing fee $100, receipt number AINSDC-8207178), filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # 1 Exhibit A - Certification, # 2 Text of Proposed Order)(Hidde, Kandi) (Entered: 06/13/2024)

2024-06-13

1

View

MOTION for Attorney(s) Stephen J. Fuzesi to Appear pro hac vice (Filing fee $100, receipt number BINSDC-8207182), filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # 1 Exhibit A - Certification, # 2 Text of Proposed Order)(Hidde, Kandi) (Entered: 06/13/2024)

2024-06-13

1

View

MOTION for Attorney(s) Thomas S. Fletcher to Appear pro hac vice (Filing fee $100, receipt number AINSDC-8207184), filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # 1 Envelope A - Certification, # 2 Text of Proposed Order)(Hidde, Kandi) (Entered: 06/13/2024)

2024-06-13

1

View

ORDER OF RECUSAL. Clerk is directed to randomly reassign case and notify parties of newly assigned Judge. Signed by Judge James R. Sweeney II on 06/14/2024. (SNB) (Entered: 06/14/2024)

2024-06-14

1

View

NOTICE of Reassignment of Case to District Judge Richard L Young. Judge James R. Sweeney II is no longer assigned to this case. Please include the new case number, 1:24-cv-1011-RLY-TAB, on all future filings in this matter. (DJH) (Entered: 06/14/2024)

2024-06-14

1

View

Summons Issued to ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., and POINT BIOPHARMA INC. (BAA) (Entered: 06/14/2024)

2024-06-14

1

View

MAGISTRATE JUDGE's NOTICE of Availability to Exercise Jurisdiction issued. (BAA) (Entered: 06/14/2024)

2024-06-14

1

View

Notice to File Rule 7.1 Disclosure Statement. (RAGS) (BAA) (Entered: 06/14/2024)

2024-06-14

1

View

RETURN of Service, filed by All Plaintiffs. All Defendants. (Attachments: # 1 Exhibit A - Affidavit of Service POINT Biopharma Global Inc., # 2 Exhibit B - Affidavit of Service POINT Biopharma Inc., # 3 Exhibit C - Affidavit of Service Eli Lilly and Co)(Hidde, Kandi) (Entered: 06/24/2024)

2024-06-24

1

View

ORDER GRANTING MOTION TO APPEAR PRO HAC VICE FILED ON BEHALF OF ATTORNEY MELISSA B. COLLINS - This cause has come before the Court upon the motion of Kandi Kilkelly Hidde of the law firm Frost Brown Todd LLP, seeking an Order granting Melissa B. Collins of Williams & Connolly LLP, leave to appear pro hac vice for the purpose of appearing as counsel on behalf of Endocyte, Inc., Novartis Pharmaceutical Corporation, and Purdue Research Foundation, in the above-styled cause only. Being fully advised, it is now ORDERED that the motion [Filing No. 5] be, and hereby is, GRANTED. Copy to Counsel via US mail. Applicant's contact information should be entered as follows: Melissa B. Collins Williams & Connolly LLP 680 Maine Avenue SW Washington, DC 20024 202-434-5000 202-434-5029 fax mcollins@wc.com Signed by Magistrate Judge Tim A. Baker on 06/26/2024. (AJG) (Entered: 06/26/2024)

2024-06-26

1

View

ORDER GRANTING MOTION TO APPEAR PRO HAC VICE FILED ON BEHALF OF ATTORNEY M. ELAINE HORN - This cause has come before the Court upon the motion of Kandi Kilkelly Hidde of the law firm Frost Brown Todd LLP, seeking an Order granting M. Elaine Horn of Williams & Connolly LLP, leave to appear pro hac vice for the purpose of appearing as counsel on behalf of Endocyte, Inc., Novartis Pharmaceutical Corporation, and Purdue Research Foundation, in the above-styled cause only. Being fully advised, it is now ORDERED that the motion [Filing No. 6] be, and hereby is, GRANTED. Copy to Counsel via US mail. Applicant's contact information should be entered as follows M. Elaine Horn Williams & Connolly LLP 680 Maine Avenue SW Washington, DC 20024 202-434-5000 202-434-5029 fax ehorn@wc.com Counsel shall registerfor electronic filing, asrequired by Local Rule5-3, within 7 days. Signed by Magistrate Judge Tim A. Baker on 06/26/2024. (AJG) (Entered: 06/26/2024)

2024-06-26

1

View

ORDER GRANTING MOTION TO APPEAR PRO HAC VICE FILED ON BEHALF OF ATTORNEY JESSAMYN S. BERNIKER - This cause has come before the Court upon the motion of Kandi Kilkelly Hidde of the law firm Frost Brown Todd LLP, seeking an Order granting Jessamyn S. Berniker of Williams & Connolly LLP, leave to appear pro hac vice for the purpose of appearing as counsel on behalf of Endocyte, Inc., Novartis Pharmaceutical Corporation, and Purdue Research Foundation, in the above-styled cause only. Being fully advised, it is now ORDERED that the motion [Filing No. 7] be, and hereby is, GRANTED. Copy to Counsel via US mail. Signed by Magistrate Judge Tim A. Baker on 06/26/2024. (AJG) (Entered: 06/26/2024)

2024-06-26

1

View

ORDER granting 8 Motion to Appear pro hac vice. Attorney Stephen J. Fuzesi for ENDOCYTE, INC.,Stephen J. Fuzesi for NOVARTIS PHARMACEUTICAL CORPORATION,Stephen J. Fuzesi for PURDUE RESEARCH FOUNDATION added. This cause has come before the Court upon the motion of Kandi Kilkelly Hidde of the law firm Frost Brown Todd LLP, seeking an Order granting Stephen J. Fuzesi of Williams & Connolly LLP, leave to appear pro hac vice for the purpose of appearing as counsel on behalf of Endocyte, Inc., Novartis Pharmaceutical Corporation, and Purdue Research Foundation, in the above-styled cause only. Being fully advised, it is now ORDERED that the motion [Filing No. 8] be, and hereby is, GRANTED. Counsel shall register for electronic filing, as required by Local Rule 5-3, within 7 days. Copy to Counsel via US mail. Signed by Magistrate Judge Tim A. Baker on 06/26/2024. (AJG) (Entered: 06/26/2024)

2024-06-26

1

View

ORDER granting 9 Motion to Appear pro hac vice. Attorney Thomas Fletcher for ENDOCYTE, INC.,Thomas Fletcher for NOVARTIS PHARMACEUTICAL CORPORATION,Thomas Fletcher for PURDUE RESEARCH FOUNDATION added - This cause has come before the Court upon the motion of Kandi Kilkelly Hidde of the law firm Frost Brown Todd LLP, seeking an Order granting Thomas S. Fletcher of Williams & Connolly LLP, leave to appear pro hac vice for the purpose of appearing as counsel on behalf of Endocyte, Inc., Novartis Pharmaceutical Corporation, and Purdue Research Foundation, in the above-styled cause only. Being fully advised, it is now ORDERED that the motion [Filing No. 9.] be, and hereby is, GRANTED. Counsel shall register for electronic filing, as required by Local Rule 5-3, within 7 days. Copy to Counsel via US mail. (AJG) (Entered: 06/26/2024)

2024-06-26

1

View

NOTICE of Appearance by William A. McKenna on behalf of Defendant ELI LILLY AND CO.. (McKenna, William) (Entered: 07/08/2024)

2024-07-08

1

View

NOTICE of Appearance by William A. McKenna on behalf of Defendants POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 07/08/2024)

2024-07-08

1

View

NOTICE of Parties' First Extension of Time re Filing a response to pleading defined by Fed. R. Civ. P. 7(a), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 07/08/2024)

2024-07-08

1

View

Rule 7.1 Disclosure Statement by ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 07/08/2024)

2024-07-08

1

View

MOTION for Attorney(s) Blaine M. Hackman to Appear pro hac vice (Filing fee $100, receipt number AINSDC-8235950), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Exhibit A - Certification, # 2 Text of Proposed Order)(McKenna, William) (Entered: 07/08/2024)

2024-07-08

1

View

MOTION for Attorney(s) Katherine A. Helm to Appear pro hac vice (Filing fee $100, receipt number AINSDC-8235980), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Exhibit A - Certification, # 2 Text of Proposed Order)(McKenna, William) (Entered: 07/08/2024)

2024-07-08

1

View

MOTION for Attorney(s) Martin J. Black to Appear pro hac vice (Filing fee $100, receipt number AINSDC-8236003), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Exhibit A - Certification, # 2 Text of Proposed Order)(McKenna, William) (Entered: 07/08/2024)

2024-07-08

1

View

MOTION for Attorney(s) Pejmon Pashai to Appear pro hac vice (Filing fee $100, receipt number AINSDC-8236025), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Exhibit A - Certification, # 2 Text of Proposed Order)(McKenna, William) (Entered: 07/08/2024)

2024-07-08

1

View

ORDER granting 25 Motion to Appear pro hac vice. Attorney Blaine M. Hackman for ELI LILLY AND CO.,Blaine M. Hackman for POINT BIOPHARMA GLOBAL INC.,Blaine M. Hackman for POINT BIOPHARMA INC. added. SEE ORDER. Copy sent to distribution list via US Mail. Signed by Magistrate Judge Tim A. Baker on 7/10/2024. (JRB) (Entered: 07/10/2024)

2024-07-10

1

View

ORDER granting 26 Motion to Appear pro hac vice. Attorney Katherine A Helm for ELI LILLY AND CO.,Katherine A Helm for POINT BIOPHARMA GLOBAL INC.,Katherine A Helm for POINT BIOPHARMA INC. added. Signed by Magistrate Judge Tim A. Baker on 7/10/2024. (JRB) (Entered: 07/10/2024)

2024-07-10

1

View

ORDER granting 27 Motion to Appear pro hac vice. Attorney Martin J. Black for ELI LILLY AND CO.,Martin J. Black for POINT BIOPHARMA GLOBAL INC.,Martin J. Black for POINT BIOPHARMA INC. added. SEE ORDER. Copy sent to distribution list via US Mail. Signed by Magistrate Judge Tim A. Baker on 7/10/2024. (JRB) (Entered: 07/10/2024)

2024-07-10

1

View

ORDER granting 28 Motion to Appear pro hac vice. Attorney Pejmon Pashai for ELI LILLY AND CO.,Pejmon Pashai for POINT BIOPHARMA GLOBAL INC.,Pejmon Pashai for POINT BIOPHARMA INC. added. SEE ORDER. Copy sent to distribution list via US Mail. Signed by Magistrate Judge Tim A. Baker on 7/10/2024. (JRB) (Entered: 07/10/2024)

2024-07-10

1

View

ORDER SETTING TELEPHONIC INITIAL PRETRIAL CONFERENCE: This case is assigned for a telephonic initial pretrial conference before United States Magistrate Judge Tim A. Baker on September 6, 2024, at 11 a.m. (Eastern Time). Parties shall participate in this conference by counsel. The information needed by counsel of record to participate in this telephonic conference will be provided by separate notification. The parties themselves may participate at their option. If a proposed Case Management Plan ("CMP") has not yet been filed, the parties are ordered to confer prior to the initial pretrial conference and prepare a proposed CMP. See Order. Signed by Magistrate Judge Tim A. Baker on 7/15/2024.(Copy mailed per Distribution list.) (LF) (Entered: 07/16/2024)

2024-07-15

1

View

NOTICE of Initial Filing in lawsuit sent to Director of U.S. Patent and Trademark Office. (Attachments: # 1 Complaint, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit) (AJG) (Entered: 07/23/2024)

2024-07-23

1

View

MOTION TO DISMISS FOR FAILURE TO STATE A CLAIM, MOTION to Dismiss for Lack of Jurisdiction, filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Text of Proposed Order)(McKenna, William) (Entered: 08/05/2024)

2024-08-05

1

View

BRIEF/MEMORANDUM in Support re 35 MOTION TO DISMISS FOR FAILURE TO STATE A CLAIM MOTION to Dismiss for Lack of Jurisdiction, filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 08/05/2024)

2024-08-05

1

View

NOTICE (Defendants' Request for Judicial Notice of Exhibits filed in Support of its Motion), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC., re 36 Brief/Memorandum in Support, 35 MOTION TO DISMISS FOR FAILURE TO STATE A CLAIM MOTION to Dismiss for Lack of Jurisdiction . (Attachments: # 1 Exhibit 1-Lantheus Holding, Inc. SEC Form 10-Q (filed May 2, 2024), # 2 Exhibit 2-A Brief History of the Center of Drug Evaluation and Research (Jan. 31, 2018), # 3 Exhibit 3- U.S. Govt Accountability Off., (GAO-17-564), Investigational New Drugs: FDA Has Taken Steps to Improve the Expanded Access Program but Should Further Clarify How Adverse Events Data Are Used (2017), # 4 Exhibit 4-Lantheus Holdings, Inc. SEC Quarterly Report (Form 10-Q) (filed Nov. 2, 2023), # 5 Exhibit 5-U.S. Nuclear Reg. Commn, Revision of 2018 Memorandum to the Regions, Licensing of Lutetium-177 (Dec. 8, 2022), # 6 Text of Proposed Order) (McKenna, William) (Entered: 08/05/2024)

2024-08-05

1

View

MOTION FOR ORAL ARGUMENT REGARDING ITS MOTION TO DISMISS PLAINTIFFS COMPLAINT PURSUANT TO RULES 12(b)(1) AND 12(b)(6), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Text of Proposed Order)(McKenna, William) (Entered: 08/05/2024)

2024-08-05

1

View

MOTION for Extension of Time to August 26, 2024 in which to 37 Notice (Other), 38 MOTION FOR ORAL ARGUMENT REGARDING ITS MOTION TO DISMISS PLAINTIFFS COMPLAINT PURSUANT TO RULES 12(b)(1) AND 12(b)(6), filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # 1 Text of Proposed Order)(Hidde, Kandi) (Entered: 08/16/2024)

2024-08-16

1

View

ORDER granting 39 Motion for Extension of Time to File - Plaintiffs, Endocyte, Inc., Novartis Pharmaceuticals Corporation, and Purdue Research Foundation, by counsel, having filed a Motion for Extension of Time to file responses to Defendants' Request for Judicial Notice of Exhibits Filed in Support of its Motion to Dismiss Plaintiffs' Complaint [ECF No. 37 ] and Defendants' Motion for Oral Argument [ECF No. 38 ] and the Court, being duly advised, now grants the motion. [Filing No. 39. IT IS THEREFORE ORDERED that Plaintiffs shall have to and including August 26, 2024, to file a response Defendants' Request for Judicial Notice and Motion for Oral Argument. Signed by Magistrate Judge Tim A. Baker on 08/19/2024. (AJG) (Entered: 08/19/2024)

2024-08-19

1

View

RESPONSE in Opposition re 35 MOTION TO DISMISS FOR FAILURE TO STATE A CLAIM MOTION to Dismiss for Lack of Jurisdiction [PLAINTIFFS' RESPONSE IN OPPOSITION TO DEFENDANTS' MOTION TO DISMISS], filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # 1 Exhibit 6 - Lantheus 2023.04.24 Press Release, # 2 Exhibit 7 - Lantheus 2024.08.20 Press Release, # 3 Exhibit 8 - Email Correspondence)(Hidde, Kandi) (Entered: 08/26/2024)

2024-08-26

1

View

Patent CASE MANAGEMENT PLAN TENDERED, filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION . (Hidde, Kandi) (Entered: 09/03/2024)

2024-09-03

1

View

ESI Supplement to CASE MANAGEMENT PLAN TENDERED, filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION . (Hidde, Kandi) (Entered: 09/03/2024)

2024-09-03

1

View

REPLY in Support of Motion re 35 MOTION TO DISMISS FOR FAILURE TO STATE A CLAIM MOTION to Dismiss for Lack of Jurisdiction, filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 09/03/2024)

2024-09-03

1

View

MOTION to Stay of Litigation Pending Decision on Defendants' Rule 12(b)(1) and 12(b)(6) Motion to Dismiss (ECF Nos. 35-36), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 09/03/2024)

2024-09-03

1

View

Unopposed MOTION to Participate in Initial Pretrial Conference, filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # 1 Text of Proposed Order Order)(Hidde, Kandi) (Entered: 09/05/2024)

2024-09-05

1

View

First MOTION for Attorney(s) Christie K. Corn to Appear pro hac vice (Filing fee $100, receipt number BINSDC-8323083), filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # 1 Text of Proposed Order)(Corn, Christie) (Entered: 09/05/2024)

2024-09-05

1

View

MOTION for Attorney(s) Max C. Accardi to Appear pro hac vice (Filing fee $100, receipt number AINSDC-8323260), filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # 1 Text of Proposed Order Proposed Order)(Accardi, Max) (Entered: 09/05/2024)

2024-09-05

1

View

ORDER granting 47 Motion to participate in initial pretrial conference. The representatives for the Plaintiffs identified in Paragraph 4 of the Motion are allowed to participate in the initial pretrial conference. Counsel for Plaintiffs shall provide the call-in information to said representatives. (MGL) (Entered: 09/06/2024)

2024-09-06

1

View

ORDER ON SEPTEMBER 6, 2024, TELEPHONIC INITIAL PRETRIAL CONFERENCE - Plaintiffs appeared in person and by counsel and Defendants appeared by counsel September 6, 2024, for a telephonic initial pretrial conference. The Court addressed issues regarding case management and settlement. Given the disagreements in the proposed Case Management Plan [Filing No. 42], as well as Defendants' motion to stay [Filing No. 45] (which is not yet ripe), the Court denied the proposed CMP. The Court will rule on Defendants' motion to stay promptly after that motion is fully briefed. If that motion is denied, the Court will order counsel to file a revised, proposed CMP. Signed by Magistrate Judge Tim A. Baker. (MGL) (Entered: 09/06/2024)

2024-09-06

1

View

ORDER granting 48 Motion to Appear pro hac vice. Attorney Christie Corn for ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION added. Signed by Magistrate Judge Tim A. Baker on 9/6/2024. (KAA) (Entered: 09/06/2024)

2024-09-06

1

View

ORDER granting 49 Motion to Appear pro hac vice. Attorney Max Accardi for ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION added. Signed by Magistrate Judge Tim A. Baker on 9/6/2024. (KAA) (Entered: 09/06/2024)

2024-09-06

1

View

RESPONSE in Opposition re 45 MOTION to Stay of Litigation Pending Decision on Defendants' Rule 12(b)(1) and 12(b)(6) Motion to Dismiss (ECF Nos. 35-36) [Plaintiffs' Response In Opposition To Defendants' Motion To Stay Discovery], filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # 1 Exhibit 1 - Lantheus Press Release, # 2 Exhibit 2 - PNT2002 ESMO Abstract)(Hidde, Kandi) (Entered: 09/17/2024)

2024-09-17

1

View

REPLY in Support of Motion re 45 MOTION to Stay of Litigation Pending Decision on Defendants' Rule 12(b)(1) and 12(b)(6) Motion to Dismiss (ECF Nos. 35-36), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 09/24/2024)

2024-09-24

1

View

DECLARATION of William A. McKenna re 55 Reply in Support of Motion by ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Exhibit 1-Study Details - Clinical Trials, # 2 Exhibit 2-Emaill Correspondence)(McKenna, William) (Entered: 09/24/2024)

2024-09-24

1

View

ORDER granting 45 Motion to Stay - Defendants' motion for stay of litigation pending decision on Defendants' Rule 12(b)(1) and 12(b)(6) motion to dismiss is granted. [Filing No. 45 .] In accordance with Plaintiffs' alternate request, the Court requires Defendants to provide regularly scheduled updates on the status of PNT2002's approval process to ensure that Plaintiffs have reasonable notice of the imminence of Defendants' commercial launch. (See Order For Additional Details.) Signed by Magistrate Judge Tim A. Baker on 10/02/2024. (AJG) (Entered: 10/02/2024)

2024-10-02

1

View

ENTRY ON DEFENDANTS' MOTION TO DISMISS PLAINTIFFS' COMPLAINT PURSUANT TO RULES 12(b)(1) AND 12(b)(6) and DEFENDANTS' MOTION FOR ORAL ARGUMENT: The court DENIES Defendants' Motion for Oral Argument (Filing No. 38) and GRANTS in part and DENIES in part Defendants' Motion to Dismiss Plaintiffs' Complaint Pursuant to Rules 12(b) (1) and 12(b)(6) (Filing No. 35 ). SEE ORDER. Signed by District Judge Richard L Young on 3/10/2025. (LF) (Entered: 03/10/2025)

2025-03-10

1

View

ORDER SETTING TELEPHONIC STATUS CONFERENCE AND FURTHER PROCEEDINGS - This matter is set for a telephonic status conference at 9:30 a.m. (Eastern Time) on April 8, 2025, before Magistrate Judge Tim A. Baker. Parties shall appear by counsel. The information needed by counsel of record to participate in this telephonic conference will be provided by separate notification. The purpose of this conference is to address case status and settlement. Three business days prior to the telephonic status conference, the parties shall confer and file a proposed Case Management Plan, which can be found on the Court's website at www.insd.uscourts.gov, addressing any remaining discovery needs, trial readiness, and the timing of a settlement conference. Signed by Magistrate Judge Tim A. Baker on 03/12/2025.(AAS) (Entered: 03/12/2025)

2025-03-12

1

View

Consent MOTION for Continuance OF TELEPHONIC STATUS CONFERENCE, filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Text of Proposed Order)(McKenna, William) (Entered: 03/27/2025)

2025-03-27

1

View

MOTION for Attorney(s) Bruce M. Wexler to Appear pro hac vice (Filing fee $100, receipt number AINSDC-8607410), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Exhibit A - Certification, # 2 Text of Proposed Order)(McKenna, William) (Entered: 03/28/2025)

2025-03-28

1

View

MOTION for Attorney(s) Eric W. Dittmann to Appear pro hac vice (Filing fee $100, receipt number AINSDC-8607424), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Exhibit A - Certification, # 2 Text of Proposed Order)(McKenna, William) (Entered: 03/28/2025)

2025-03-28

1

View

MOTION for Attorney(s) Candace Polster to Appear pro hac vice (Filing fee $100, receipt number AINSDC-8607445), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Envelope A - Certification, # 2 Text of Proposed Order)(McKenna, William) (Entered: 03/28/2025)

2025-03-28

1

View

ORDER GRANTING MOTION TO CONTINUE AND RESET TELEPHONIC STATUS CONFERENCE - This matter is before the Court on Defendants' Consent Motion for Continuance of Telephonic Status Conference, and the Court being duly advised, hereby grants the motion. [Filing No. 60 .] IT IS THEREFORE ORDERED that the telephonic status conference currently set for April 8, 2025, is vacated and reset for 2:30 p.m. (Eastern Time) on April 22, 2025. The information needed by counsel of record to participate in this telephonic conference will be provided by separate notification. The purpose of this conference is to address case status and settlement. Three business days prior to the telephonic status conference, the parties shall confer and file a proposed Case Management Plan, which can be found on the Court's website at www.insd.uscourts.gov, addressing any remaining discovery needs, trial readiness, and the timing of a settlement conference Signed by Magistrate Judge Tim A. Baker on 03/28/2025. (AJG) (Entered: 03/28/2025)

2025-03-28

1

View

ORDER granting 61 Motion to Appear pro hac vice. Attorney Bruce M. Wexler for ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., and POINT BIOPHARMA INC. added. Counsel shall register for electronic filing, as required by Local Rule 5-3, within 7 days. Signed by Magistrate Judge Tim A. Baker on 4/1/2025 (Copy mailed to Bruce M. Wexler). (LBT) (Entered: 04/01/2025)

2025-04-01

1

View

ORDER granting 62 Motion to Appear pro hac vice. Attorney Eric W. Dittmann for ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC. added. Counsel shall register for electronic filing, as required by Local Rule 5-3, within 7 days. Signed by Magistrate Judge Tim A. Baker on 4/1/2025 (Copy mailed to Eric W. Dittmann). (LBT) (Entered: 04/01/2025)

2025-04-01

1

View

ORDER granting 63 Motion to Appear pro hac vice. Attorney Candace Polster for ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC. added. Counsel shall register for electronic filing, as required by Local Rule 5-3, within 7 days. Signed by Magistrate Judge Tim A. Baker on 4/1/2025 (Copy mailed to Candace Polster). (LBT) (Entered: 04/01/2025)

2025-04-01

1

View

Consent MOTION for Extension of Time to April 25, 2025 for Defendants' to Answer Plaintiffs' Complaint and for Plaintiffs' to Respond Thereto, filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Text of Proposed Order)(McKenna, William) (Entered: 04/02/2025)

2025-04-02

1

View

ORDER granting 68 MOTION FOR EXTENSION OF TIME FOR DEFENDANTS TO ANSWER PLAINTIFFS' COMPLAINT AND FOR PLAINTIFFS TO RESPOND THERETO: IT IS THEREFORE ORDERED that Defendants' answer is now due April 25, 2025 and Plaintiffs' response thereto, if any, is now due May 23, 2025. See Order. Signed by Magistrate Judge Tim A. Baker on 4/3/2025. (LF) (Entered: 04/03/2025)

2025-04-03

1

View

CASE MANAGEMENT PLAN TENDERED, filed by Plaintiff NOVARTIS PHARMACEUTICAL CORPORATION . (Hidde, Kandi) (Entered: 04/17/2025)

2025-04-17

1

View

Submission ESI Supplement to Case Management Plan, filed by Plaintiff NOVARTIS PHARMACEUTICAL CORPORATION. (Hidde, Kandi) (Entered: 04/17/2025)

2025-04-17

1

View

ORDER: PATENT CASE MANAGEMENT PLAN - Dispositive Motions due by 8/26/2026. Discovery due by 2/6/2026. Status Conference set for 9/23/2025 01:30 PM in Telephonic before Magistrate Judge Tim A. Baker. Approved and So Ordered. Signed by Magistrate Judge Tim A. Baker on 4/23/2025.(KAA) (Entered: 04/23/2025)

2025-04-23

1

View

DEFENDANTS' ANSWER to 1 Complaint, COUNTERCLAIM against All Plaintiffs, filed by All Defendants. (Attachments: # 1 Supplement, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit)(Polster, Candace) (Entered: 04/25/2025)

2025-04-25

1

View

NOTICE of Answer in lawsuit sent to Director of U.S. Patent and Trademark Office. (Attachments: # 1 Answer) (AJG) (Entered: 05/15/2025)

2025-05-15

1

View

ANSWER to 74 Answer to ComplaintCounterclaim, filed by All Plaintiffs.(Hidde, Kandi) (Entered: 05/16/2025)

2025-05-16

1

View

NOTICE of Initial Filing in lawsuit sent to Director of U.S. Patent and Trademark Office. (Attachments: # 1 Complaint and Answer) (AJG) (Entered: 06/30/2025)

2025-06-30

1

View

STIPULATION of Dismissal WITHOUT PREJUDICE, as to Plaintiffs PURDUE RESEARCH FOUNDATION, NOVARTIS PHARMACEUTICAL CORPORATION, ENDOCYTE, INC., Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC., Counter Claimants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC., Counter Defendants ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION, filed by All Plaintiffs. (Hidde, Kandi) (Entered: 07/10/2025)

2025-07-10

1

View

MARGINAL ENTRY - ACKNOWLEDGED. Case is dismissed without prejudice. Signed by District Judge Richard L Young on 7/18/25.(RSF) (Entered: 07/18/2025)

2025-07-18

1

View

NOTICE of Final Determination in lawsuit sent to Director of U.S. Patent and Trademark Office. (Attachments: # 1 Dismissal) (CKM) (Entered: 08/18/2025)

2025-08-18

1

View

Overview

Parties

Defendant

ELI LILLY AND CO. Follow

Represented By

POINT BIOPHARMA INC. Follow

Represented By

POINT BIOPHARMA GLOBAL INC. Follow

Represented By

Plaintiff

PURDUE RESEARCH FOUNDATION Follow

Represented By

NOVARTIS PHARMACEUTICAL CORPORATION Follow

Represented By

ENDOCYTE, INC. Follow

Represented By

Court & Judges

Patents Involved

Docket Entries

COMPLAINT against All Defendants, filed by All Plaintiffs. (Filing fee $405, receipt number AINSDC-8206974) (Attachments: # 1 Civil Cover Sheet, # 2 Proposed Summons, # 3 Exhibit A -10,624,970 Patent Certified, # 4 Exhibit B Nov 11, 2022 POINT-Lantheus Agreement)(Hidde, Kandi) (Entered: 06/13/2024)

COMPLAINT against All Defendants, filed by All Plaintiffs. (Filing fee $405, receipt number AINSDC-8206974) (Attachments: # 1 Civil Cover Sheet, # 2 Proposed Summons, # 3 Exhibit A -10,624,970 Patent Certified, # 4 Exhibit B Nov 11, 2022 POINT-Lantheus Agreement)(Hidde, Kandi) (Entered: 06/13/2024)

COMPLAINT against All Defendants, filed by All Plaintiffs. (Filing fee $405, receipt number AINSDC-8206974) (Attachments: # 1 Civil Cover Sheet, # 2 Proposed Summons, # 3 Exhibit A -10,624,970 Patent Certified, # 4 Exhibit B Nov 11, 2022 POINT-Lantheus Agreement)(Hidde, Kandi) (Entered: 06/13/2024)

COMPLAINT against All Defendants, filed by All Plaintiffs. (Filing fee $405, receipt number AINSDC-8206974) (Attachments: # 1 Civil Cover Sheet, # 2 Proposed Summons, # 3 Exhibit A -10,624,970 Patent Certified, # 4 Exhibit B Nov 11, 2022 POINT-Lantheus Agreement)(Hidde, Kandi) (Entered: 06/13/2024)

COMPLAINT against All Defendants, filed by All Plaintiffs. (Filing fee $405, receipt number AINSDC-8206974) (Attachments: # 1 Civil Cover Sheet, # 2 Proposed Summons, # 3 Exhibit A -10,624,970 Patent Certified, # 4 Exhibit B Nov 11, 2022 POINT-Lantheus Agreement)(Hidde, Kandi) (Entered: 06/13/2024)

NOTICE of Appearance by Kandi Kilkelly Hidde on behalf of Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Hidde, Kandi) (Entered: 06/13/2024)

NOTICE of Appearance by Patricia Roman Hass on behalf of Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Roman Hass, Patricia) (Entered: 06/13/2024)

Rule 7.1 Disclosure Statement by ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Hidde, Kandi) (Entered: 06/13/2024)

ORDER OF RECUSAL. Clerk is directed to randomly reassign case and notify parties of newly assigned Judge. Signed by Judge James R. Sweeney II on 06/14/2024. (SNB) (Entered: 06/14/2024)

NOTICE of Reassignment of Case to District Judge Richard L Young. Judge James R. Sweeney II is no longer assigned to this case. Please include the new case number, 1:24-cv-1011-RLY-TAB, on all future filings in this matter. (DJH) (Entered: 06/14/2024)

Summons Issued to ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., and POINT BIOPHARMA INC. (BAA) (Entered: 06/14/2024)

MAGISTRATE JUDGE's NOTICE of Availability to Exercise Jurisdiction issued. (BAA) (Entered: 06/14/2024)

Notice to File Rule 7.1 Disclosure Statement. (RAGS) (BAA) (Entered: 06/14/2024)

RETURN of Service, filed by All Plaintiffs. All Defendants. (Attachments: # 1 Exhibit A - Affidavit of Service POINT Biopharma Global Inc., # 2 Exhibit B - Affidavit of Service POINT Biopharma Inc., # 3 Exhibit C - Affidavit of Service Eli Lilly and Co)(Hidde, Kandi) (Entered: 06/24/2024)

NOTICE of Appearance by William A. McKenna on behalf of Defendant ELI LILLY AND CO.. (McKenna, William) (Entered: 07/08/2024)

NOTICE of Appearance by William A. McKenna on behalf of Defendants POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 07/08/2024)

NOTICE of Parties' First Extension of Time re Filing a response to pleading defined by Fed. R. Civ. P. 7(a), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 07/08/2024)

Rule 7.1 Disclosure Statement by ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 07/08/2024)

ORDER granting 26 Motion to Appear pro hac vice. Attorney Katherine A Helm for ELI LILLY AND CO.,Katherine A Helm for POINT BIOPHARMA GLOBAL INC.,Katherine A Helm for POINT BIOPHARMA INC. added. Signed by Magistrate Judge Tim A. Baker on 7/10/2024. (JRB) (Entered: 07/10/2024)

NOTICE of Initial Filing in lawsuit sent to Director of U.S. Patent and Trademark Office. (Attachments: # 1 Complaint, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit) (AJG) (Entered: 07/23/2024)

MOTION TO DISMISS FOR FAILURE TO STATE A CLAIM, MOTION to Dismiss for Lack of Jurisdiction, filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Text of Proposed Order)(McKenna, William) (Entered: 08/05/2024)

BRIEF/MEMORANDUM in Support re 35 MOTION TO DISMISS FOR FAILURE TO STATE A CLAIM MOTION to Dismiss for Lack of Jurisdiction, filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 08/05/2024)

MOTION FOR ORAL ARGUMENT REGARDING ITS MOTION TO DISMISS PLAINTIFFS COMPLAINT PURSUANT TO RULES 12(b)(1) AND 12(b)(6), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Text of Proposed Order)(McKenna, William) (Entered: 08/05/2024)

Patent CASE MANAGEMENT PLAN TENDERED, filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION . (Hidde, Kandi) (Entered: 09/03/2024)

ESI Supplement to CASE MANAGEMENT PLAN TENDERED, filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION . (Hidde, Kandi) (Entered: 09/03/2024)

REPLY in Support of Motion re 35 MOTION TO DISMISS FOR FAILURE TO STATE A CLAIM MOTION to Dismiss for Lack of Jurisdiction, filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 09/03/2024)

MOTION to Stay of Litigation Pending Decision on Defendants' Rule 12(b)(1) and 12(b)(6) Motion to Dismiss (ECF Nos. 35-36), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 09/03/2024)

Unopposed MOTION to Participate in Initial Pretrial Conference, filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # 1 Text of Proposed Order Order)(Hidde, Kandi) (Entered: 09/05/2024)

First MOTION for Attorney(s) Christie K. Corn to Appear pro hac vice (Filing fee $100, receipt number BINSDC-8323083), filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # 1 Text of Proposed Order)(Corn, Christie) (Entered: 09/05/2024)

ORDER granting 48 Motion to Appear pro hac vice. Attorney Christie Corn for ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION added. Signed by Magistrate Judge Tim A. Baker on 9/6/2024. (KAA) (Entered: 09/06/2024)

ORDER granting 49 Motion to Appear pro hac vice. Attorney Max Accardi for ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION added. Signed by Magistrate Judge Tim A. Baker on 9/6/2024. (KAA) (Entered: 09/06/2024)

REPLY in Support of Motion re 45 MOTION to Stay of Litigation Pending Decision on Defendants' Rule 12(b)(1) and 12(b)(6) Motion to Dismiss (ECF Nos. 35-36), filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 09/24/2024)

DECLARATION of William A. McKenna re 55 Reply in Support of Motion by ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Exhibit 1-Study Details - Clinical Trials, # 2 Exhibit 2-Emaill Correspondence)(McKenna, William) (Entered: 09/24/2024)

Consent MOTION for Continuance OF TELEPHONIC STATUS CONFERENCE, filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # 1 Text of Proposed Order)(McKenna, William) (Entered: 03/27/2025)

CASE MANAGEMENT PLAN TENDERED, filed by Plaintiff NOVARTIS PHARMACEUTICAL CORPORATION . (Hidde, Kandi) (Entered: 04/17/2025)

Submission ESI Supplement to Case Management Plan, filed by Plaintiff NOVARTIS PHARMACEUTICAL CORPORATION. (Hidde, Kandi) (Entered: 04/17/2025)

DEFENDANTS' ANSWER to 1 Complaint, COUNTERCLAIM against All Plaintiffs, filed by All Defendants. (Attachments: # 1 Supplement, # 2 Exhibit, # 3 Exhibit, # 4 Exhibit, # 5 Exhibit, # 6 Exhibit, # 7 Exhibit, # 8 Exhibit, # 9 Exhibit, # 10 Exhibit)(Polster, Candace) (Entered: 04/25/2025)

NOTICE of Answer in lawsuit sent to Director of U.S. Patent and Trademark Office. (Attachments: # 1 Answer) (AJG) (Entered: 05/15/2025)

ANSWER to 74 Answer to ComplaintCounterclaim, filed by All Plaintiffs.(Hidde, Kandi) (Entered: 05/16/2025)

NOTICE of Initial Filing in lawsuit sent to Director of U.S. Patent and Trademark Office. (Attachments: # 1 Complaint and Answer) (AJG) (Entered: 06/30/2025)

MARGINAL ENTRY - ACKNOWLEDGED. Case is dismissed without prejudice. Signed by District Judge Richard L Young on 7/18/25.(RSF) (Entered: 07/18/2025)

NOTICE of Final Determination in lawsuit sent to Director of U.S. Patent and Trademark Office. (Attachments: # 1 Dismissal) (CKM) (Entered: 08/18/2025)

Track Case Updates

ELI LILLY AND CO.

POINT BIOPHARMA INC.

POINT BIOPHARMA GLOBAL INC.

PURDUE RESEARCH FOUNDATION

NOVARTIS PHARMACEUTICAL CORPORATION

ENDOCYTE, INC.